Abstract
Background:
Apolipoprotein E (APOE) regulates lipid metabolism and neuronal repair, yet its alleles show contrasting effects on hemorrhagic stroke (HS) risk. While some variants increase susceptibility, others appear protective, leading to inconsistent findings. This meta-analysis systematically evaluates the APOE-HS association to clarify its role in stroke pathophysiology.
Methods:
A comprehensive literature search was conducted across multiple databases up to January 31, 2025, using the keywords: (“Apolipoprotein E” OR “APOE” OR “APOE genotype”) AND (“Single Nucleotide Polymorphisms” OR “SNP”) AND (“Hemorrhagic stroke” OR “HS” OR “Intracerebral Hemorrhage” OR “ICH”). The APOE ε3/ε3 genotype served as the reference genotype in all studies, and only those studies with ε3/ε3 genotype were included in the analysis. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated, and statistical analyses were performed using STATA version 13.0 (StataCorp LLC, College Station, Texas, United States).
Results:
A total of 24 studies comprising 8,269 HS patients and 26,321 controls were included. Meta-analysis revealed a significant association of APOE ε2/ε2 (OR = 1.93, 95% CI = 1.32–2.81), ε4/ε4 (OR = 1.60, 95% CI = 1.21–2.13), ε2/ε4 (OR = 1.81, 95% CI = 1.34–2.44), ε2 (OR = 1.23, 95% CI = 1.12–1.35), and ε4 (OR = 1.31, 95% CI = 1.14–1.51) with an increased risk of HS.
Conclusion:
Our findings suggest that APOE ε2/ε2, ε2/ε4, ε2, and ε4/ε4 genotypes and the ε4 allele are associated with an elevated risk of HS. These results highlight the potential role of APOE genotypes in HS susceptibility and warrant further investigation.
1 Introduction
Stroke remains a leading global cause of mortality and disability, with approximately 15 million cases and 5 million deaths annually, placing a substantial burden on healthcare systems and caregivers (WHO, n.d.). Low-income countries like India face an escalating stroke crisis exacerbated by limited access to early intervention and preventive strategies (Feigin et al., 2021). Hemorrhagic stroke (HS), resulting from the rupture of intracranial blood vessels, is classified into intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), contributing to 27.9 and 9.7% of new stroke cases, respectively (Unnithan et al., 2022; Feigin et al., 2021). Among these, ICH is notably more prevalent in Asian populations, with a disproportionately high mortality and disability rate. Despite its severe impact, the clinical understanding of HS remains incomplete, as multiple risk factors contribute to its onset and progression (Wang et al., 2022; de Rooij et al., 2007).
In recent years, genetic studies have played a crucial role in uncovering the underlying mechanisms of HS. Genome-wide association studies (GWAS) have identified potential candidate genes linked to HS susceptibility, shedding light on genetic influences in disease risk (Nie et al., 2019). Among these, the Apolipoprotein E (APOE) gene, located on chromosome 19, encodes a 317-amino acid glycoprotein involved in lipid metabolism and neuronal repair. The APOE gene exists in three major alleles—ε2, ε3, and ε4, forming six distinct genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4), with ε3/ε3 being the most common in the general population (Nie et al., 2019; Sudlow et al., 2006). APOE functions as a ligand for lipoprotein receptors, playing a critical role in plasma lipid regulation and transport (Sudlow et al., 2006; ScienceDirect Topics, n.d.). However, polymorphisms in APOE, particularly ε2 and ε4, have been associated with altered lipid metabolism and an increased risk of cerebrovascular diseases (Huang and Mahley, 2014).
Although prior studies have explored the relationship between APOE polymorphisms and stroke risk, findings remain inconsistent across populations and ethnicities (Huang and Mahley, 2014). Recent meta-analyses suggest that ε2 and ε4 alleles may be linked to an increased risk of ICH, but these associations vary across different demographic groups (Nie et al., 2019; Marini et al., 2019). Given these uncertainties, our study systematically analyzes and integrates existing evidence to provide a comprehensive assessment of the association between APOE genotypes and HS risk. By incorporating data from multiple studies, this meta-analysis aims to clarify genetic contributions to HS susceptibility and refine our understanding of APOE's role in stroke pathophysiology.
2 Methods
2.1 Literature search
We conducted this systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Page et al., 2021). A comprehensive literature search was performed across multiple electronic databases, including PubMed, EMBASE, Cochrane Library, Scopus, and CINAHL, up to January 31, 2025. The search strategy incorporated relevant Medical Subject Headings (MeSH) and keywords, such as “Apolipoprotein E” (APOE), “APOE genotype,” “APOE ε2” and “APOE ε4,” alleles and their corresponding genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε4, and ε4/ε4), along with terms related to HS, ICH, cerebral hemorrhage, brain hemorrhage, and intracranial hemorrhage.
Two independent researchers (MN and AR) conducted the search, focusing exclusively on human studies without imposing language or publication date restrictions. To ensure a comprehensive dataset, we manually screened the reference lists of included studies, review articles, and previous meta-analyses for additional eligible studies.
2.1.1 Study selection criteria
2.1.1.1 Population (P)
Individuals aged ≥18 years with a clinically confirmed hemorrhagic stroke (HS) diagnosis based on CT or MRI.
2.1.1.2 Intervention/exposure (I)
Studies reporting APOE allelic frequencies (ε2, ε3, and ε4) in both HS patients and control groups.
2.1.1.3 Comparator (C)
Individuals without a history of stroke served as the control group.
2.1.1.4 Outcomes (O)
Primary outcome:
° Association between APOE genotypes (ε2/ε2 and ε4/ε4) and HS risk.
Secondary outcomes:
° Association of ε2/ε3, ε2/ε4, and ε3/ε4 genotypes with HS risk.
° Association of ε2 and ε4 alleles with HS risk.
° HS risk based on APOE genotype across different population subgroups.
° HS risk based on hemorrhage location.
2.1.1.5 Study selection (S)
Inclusion criteria:
° Published case-control, cross-sectional, or cohort studies.
° A control group without prior stroke history must be included.
Exclusion criteria:
° Duplicate publications or redundant data.
2.2 Data extraction
Based on the eligibility criteria, we screened the titles and abstracts of the literature from the available electronic databases. We gathered the following information from each included study: the first author's name, publication year, ethnicity, country, study design, study period, target population, mean age, sex, sample size (number of HS cases and healthy controls), type of hemorrhage, matching criteria, APOE genotyping method, allelic distribution of APOE genotypes in HS cases and healthy controls, and source of control. The ethnicities of the populations were classified as Asian or Caucasian. We requested any missing data from the corresponding authors of the articles. Any disagreements were resolved through consensus among all involved authors.
2.3 Data evaluation and validation
The genotyping studies included in the systematic review and meta-analysis were carefully reviewed for APOE genotypes and alleles to ensure the quality of their genotyping methodology and data capture. Most studies used the ε3 allele, and the ε3/ε3 genotype was used as the reference to assess associations between the ε2 and ε4 alleles and their genotypes and the ε3 allele. While reviewing the remaining studies that did not explicitly mention the use of a reference genotype, it was evident that the ε3 allele was used in the experiments, as the results all involved variations in the ε2 and ε4 alleles with risk association, and the ε3 allele and its genotype showed protective association or no association. Therefore, the authors of these studies were contacted to ascertain whether the ε3 allele and the ε3/ε3 genotype were used as genotyping references for the remaining alleles. The respective authors confirmed that the ε3 allele was used as a reference standard for all the analyses. Hence, our meta-analysis assessed the association of risk with the ε2 and ε4 alleles, and with the ε3 allele and the ε3/ε3 genotype as the reference.
2.4 Quality assessment
The methodological quality of the included studies was independently assessed by two reviewers (MN and AR) using the Newcastle-Ottawa Scale (NOS) (Kansagara et al., 2017), which evaluates selection, comparability, and outcome/exposure. Studies were categorized as high (≥7 points), moderate (4–6 points), or low ( ≤ 3 points) quality. Discrepancies were resolved through discussion with a third reviewer (PK).
2.5 Risk of bias assessment
Publication bias was assessed using Begg's funnel plot, while Egger's linear regression test evaluated plot asymmetry (Egger et al., 1997; Begg and Mazumdar, 1994). Sensitivity analyses were conducted to assess selection bias and heterogeneity by sequentially removing individual studies.
2.6 Genetic model of assessment
To assess the overall genetic risk association of the current APOE-based study with hemorrhagic stroke, both genotypic and allele-based models were used for comparative analyses against the reference allele ε3 and the genotype ε3/ε3, respectively. More importantly, the risk assessment in the genotypic model used a codominant comparison of APOE genotypes relative to the reference genotype. All the included studies were assessed for the Hardy-Weinberg equilibrium based on the availability of data from the control groups. The remaining studies were excluded from the final analysis.
2.7 Statistical analysis
A meta-analysis was performed to evaluate the association between APOE alleles/genotypes and HS risk, calculating pooled odds ratios (ORs) with 95% CIs. Heterogeneity was assessed using the I2 statistic, with < 50% indicating low and >50% suggesting moderate to high heterogeneity (Higgins et al., 2003). A fixed-effect model (Mantel and Haenszel, 1959) was applied for I2 < 50%, while a random-effect model (DerSimonian, 1996) was used for I2 > 50%. Subgroup analysis by ethnicity and meta-regression explored sources of heterogeneity. Statistical analyses were conducted in STATA 13.0, with p < 0.05 considered statistically significant. However, the results must be interpreted cautiously due to multiple testing, which can lead to a Type I error.
3 Results
3.1 Literature search
The initial database search identified 1,849 articles, of which 1,764 were excluded after screening titles and abstracts. The full texts of 91 studies were assessed, with 67 excluded due to reviews, editorials, prior meta-analyses, non-hemorrhagic stroke studies, absence of control groups, or incomplete data. Finally, 24 studies met the eligibility criteria and were included in the systematic review and meta-analysis. The PRISMA flowchart (Figure 1) illustrates the study selection process.
Figure 1
3.2 Characteristics of eligible studies
The included studies, published between 1996 and 2024, examined multiple ethnicities across various geographic regions. Of the 24 studies, eight focused on Asian populations (Chowdhury et al., 2001; Ganaie et al., 2020; Das et al., 2016; Zhang et al., 2012; Kokubo et al., 2000; Misra et al., 2013; Nakata et al., 1997; Jiang et al., 2024), 19 on Caucasian (Catto et al., 1996; Duzenli et al., 2004; Martini et al., 2012; Seifert et al., 2006; Basun et al., 1996; Biffi et al., 2010; Garcia et al., 1999; Greenberg et al., 1996; McCarron and Nicoll, 1998; Tasdemir et al., 2008; Woo et al., 2013, 2005, 2002; Sawyer et al., 2018; Hostettler et al., 2022), three on African (Biffi et al., 2010; Sawyer et al., 2018; Atadzhanov et al., 2013), three on Hispanic (Biffi et al., 2010; Sawyer et al., 2018), and one on a mixed population (Sawyer et al., 2018). Among the Asian studies, three were conducted in India (Ganaie et al., 2020; Das et al., 2016; Misra et al., 2013), two in Japan and China each (Kokubo et al., 2000; Nakata et al., 1997), and one in Bangladesh (Chowdhury et al., 2001). Out of the 19 Caucasian studies, eight were performed in the American (USA) (Martini et al., 2012; Biffi et al., 2010; Greenberg et al., 1996; Woo et al., 2013, 2005, 2002; Sawyer et al., 2018) population, three in the British (Catto et al., 1996; McCarron and Nicoll, 1998; Hostettler et al., 2022) population, two in the Turkish (Duzenli et al., 2004; Tasdemir et al., 2008) population, two in the Swedish (Basun et al., 1996; Biffi et al., 2010) population, two in the Austrian (Seifert et al., 2006; Biffi et al., 2010) population, and one each in the Polish (Biffi et al., 2010) and Portuguese (Garcia et al., 1999) populations. Amongst the three African studies, two were conducted in the American (USA) (Biffi et al., 2010; Sawyer et al., 2018) population, and one was in the Zambian (Atadzhanov et al., 2013) population. Additionally, two of the three Hispanic studies were performed in the Spanish (Biffi et al., 2010) population, and one was in the American (USA) (Sawyer et al., 2018) population. Study quality varied, with six rated medium and 18 high. Seventeen were population-based, seven hospital-based, and most followed a case-control design, with two retrospective cohorts and one cross-sectional study. Table 1 provides an overview of baseline characteristics and quality assessments.
Table 1
| S. no. | Study author and year | Country | Ethnicity | Study period | Study design | Type of hemorrhage | Sample size (case/control) | Genotyping method | Matching criteria | Source of control | NOS quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Atadzhanov et al. (2013) | Zambia | African | June–December, 2010 | CCS | HS | 18/116 | Taqman genotype sequencing | Age-sex | HB | 8 |
| 2 | Catto et al. (1996) | UK | Caucasian | CCS | PICH | 60/289 | PCR | Age-sex | PB | 8 | |
| 3 | Chowdhury et al. (2001) | Bangladesh | Asian | April 1998–February 1999 | CCS | HS | 80/190 | PCR-RFLP | Age-sex | PB | 8 |
| 4 | Das et al. (2016) | India | Asian | September 2007–December 2014 | CCS | HS | 250/620 | PCR-RFLP | Age-sex | PB | 9 |
| 5 | Duzenli et al. (2004) | Turkey | Caucasian | CCS | HS | 41/126 | PCR | Age-sex | PB | 6 | |
| 6 | Ganaie et al. (2020) | India | Asian | September 2012–2015 | CCS | HS | 68/108 | PCR | Age-sex | HB | 7 |
| 7 | Martini et al. (2012) | USA | Caucasian | December 1997–August 2001; July 2002–December 2006 | CCS | ICH | 597/1,548 | PCR | Age-sex | PB | 7 |
| 8 | Seifert et al. (2006) | Austria | Caucasian | October 1997–December 2000 | CCS | Lobar and non-lobar ICH | 193/280 | PCR-RFLP | PB | 4 | |
| 9 | Zhang et al. (2012) | China | Asian | 2008–2010 | CCS | ICH | 180/180 | PCR-RFLP | HB | 8 | |
| 10 | Basun et al. (1996) | Sweden | Caucasian | 1969–1994 | RCS | Prior ICH | 50/827 | PCR | PB | 6 | |
| Subsequent ICH | 87/827 | ||||||||||
| 11 | Biffi et al. (2010) GOCHA | USA | Caucasian | CCS | Lobar ICH | 398/555 | Genotype sequencing | PB | 9 | ||
| Deep ICH | 312/555 | ||||||||||
| Biffi et al. (2010) GERFHS | USA | Caucasian | June 1997 and February 2000 | CCS | Lobar ICH | 203/1,304 | Genotype sequencing | PB | |||
| Deep ICH | 337/1,304 | ||||||||||
| Biffi et al. (2010) JUHSS | Poland | Caucasian | April 1998–May 2007 | CCS | Lobar ICH | 102/429 | Genotype sequencing | PB | |||
| Deep ICH | 130/429 | ||||||||||
| Biffi et al. (2010) MUG-ICH | Austria | Caucasian | 2002 and 2006 | CCS | Lobar ICH | 77/1,023 | Genotype sequencing | PB | |||
| Deep ICH | 114/1,023 | ||||||||||
| Biffi et al. (2010) HM-ICH | Spain | Hispanic | January to December 1996 | CCS | Lobar ICH | 66/185 | Genotype sequencing | PB | |||
| Deep ICH | 103/185 | ||||||||||
| Biffi et al. (2010) LUHSS | Sweden | Caucasian | October 1997 and December 2000 | CCS | Lobar ICH | 42/161 | Genotype sequencing | PB | |||
| Deep ICH | 89/161 | ||||||||||
| Biffi et al. (2010) VHH-ICH | Spain | Hispanic | 10-year period | CCS | Lobar ICH | 43/87 | Genotype sequencing | PB | |||
| Deep ICH | - | ||||||||||
| Biffi et al. (2010) US-AA | USA | African | CCS | Lobar ICH | 63/297 | Genotype sequencing | PB | ||||
| Deep ICH | 110/297 | ||||||||||
| 12 | Garcia et al. (1999) | Portugal | Caucasian | CCS | Lobar ICH | 24/24 | PCR | Age-sex | PB | 9 | |
| Deep ICH | 24/24 | Age-sex | |||||||||
| 13 | Greenberg et al. (1996) | USA | Caucasian | CCS | Lobar Hemorrhage | 45/3,798 | PCR | PB | 5 | ||
| Non-lobar Hemorrhage | 18/3,798 | ||||||||||
| 14 | Kokubo et al. (2000) | Japan | Asian | November 1997–June 1999 | CCS | ICH | 84/1,126 | PCR | PB | 6 | |
| 15 | McCarron and Nicoll (1998) | UK | Caucasian | CCS | SAH | 96/406 | PCR | HB | 5 | ||
| Deep Hemorrhage | 71/406 | ||||||||||
| CAA Hemorrhage | 40/406 | ||||||||||
| 16 | Misra et al. (2013) | India | Asian | CCS | RICH | 33/188 | PCR | Age-sex | PB | 8 | |
| NRICH | 101/188 | Age-sex | |||||||||
| 17 | Nakata et al. (1997) | Japan | Asian | July 1992–December 1995 | CCS | HS | 38/38 | PCR | Age-sex | HB | 8 |
| 18 | Sawyer et al. (2018) | USA | Mixed | September 2009–July 2016 | CCS | Total ICH | 907/2,660 | PCR, Taqman SNP genotyping | Age-sex | PB | 9 |
| Caucasian | White ICH | 401/979 | Age-sex | ||||||||
| Hispanic | Hispanic ICH | 269/795 | Age-sex | ||||||||
| African | Black ICH | 237/886 | Age-sex | ||||||||
| 19 | Tasdemir et al. (2008) | Turkey | Caucasian | Septeber 2005–June 2006 | CCS | PICH | 35/30 | PCR, ApoE detection kit | Age-sex | HB | 9 |
| 20 | Woo et al. (2005) | USA | Caucasian | May 1997–December 2002 | CCS | Lobar ICH | 102/187 | Taqman assay | Age-sex | PB | 7 |
| 21 | Woo et al. (2013) | USA | Caucasian | July 2008–June 2013 | CCS | Lobar ICH | 204/508 | PCR | Age-sex | PB | 9 |
| Non-lobar ICH | 354/936 | Age-sex | |||||||||
| 22 | Woo et al. (2002) | USA | Caucasian | June 1997 and February 1998 | CCS | All ICH | 188/366 | PCR | Age-sex | PB | 9 |
| June 1997 and February 1999 | Lobar ICH | 67/131 | Age-sex | ||||||||
| June 1997 and February 2000 | Non-lobar ICH | 121/235 | Age-sex | ||||||||
| 23 | Hostettler et al. (2022) | UK | Caucasian | CCS | ICH | 907/2,636 | Genotype sequencing | PB | 7 | ||
| 24 | Jiang et al. (2024) | China | Asian | September 2020–September 2022 | RCS | ICH | 153/60 | QF-PCR | HB | 7 |
Characteristics of the included studies in the meta-analysis depicting the association between APOE allele and genotype and the risk of hemorrhagic stroke in adult patients.
RCS, Retrospective cohort study; CCS, case-control study; HB, hospital based; PB, population based; HS, hemorrhagic stroke; ICH, intracerebral hemorrhage; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; UK, United Kingdom; USA, United States of America; SNP, single nucleotide polymorphism; PICH, primary intracerebral hemorrhage; SAH, subarachnoid hemorrhage; CAA, cerebral amyloid angiopathy; RICH, recurrent intracerebral hemorrhage; NRICH, non-recurrent intracerebral hemorrhage; APOE, apolipoprotein E; QF-PCR, quantitative fluorescent polymerase chain reaction.
3.3 Primary outcomes
3.3.1 Association between the APOE ε2/ε2 genotype and the risk of hemorrhagic stroke
The meta-analysis included 11 studies with 2,411 cases and 6,900 controls assessing the association between the ε2/ε2 genotype of the APOE gene and hemorrhagic stroke (HS) risk. A significant overall association was observed (OR: 1.93, 95% CI = 1.32–2.81, I2 = 0%). Subgroup analysis by ethnicity revealed no significant association in the Asian population (815 cases, 2,284 controls; OR: 1.59, 95% CI = 0.80–3.16, I2 = 0%), while the Caucasian population (1,596 cases, 4,616 controls) showed a significant association (OR: 2.20, 95% CI = 1.32–3.64, I2 = 13.1%). The results are illustrated in Figure 2a and Table 2.
Figure 2
Table 2
| Population | Sample size (cases/control) | OR (95% CI) | I2 (%) | Publication bias (Egger p-value) | Meta-regression (p-value) |
|---|---|---|---|---|---|
| Overall (ε2/ε2) | 2,411/6,900 | 1.93 (1.32, 2.81) | 0 | 0.494 | 0.845 |
| Asian (ε2/ε2) | 815/2,284 | 1.59 (0.80, 3.16) | 0 | ||
| Caucasian (ε2/ε2) | 1,596/4,616 | 2.20 (1.32, 3.64) | 13.1 | ||
| Overall (ε4/ε4) | 2,590/7,603 | 1.60 (1.21, 2.13) | 3.1 | 0.760 | 0.142 |
| Asian (ε4/ε4) | 797/1,426 | 1.78 (0.73, 4.37) | 34.2 | ||
| Caucasian (ε4/ε4) | 1,775/6,061 | 1.63 (1.20, 2.20) | 0 | ||
| Overall (ε2/ε3) | 2,572/7,383 | 0.95 (0.54, 1.65) | 90.7 | 0.599 | 0.225 |
| Asian (ε2/ε3) | 815/2,284 | 0.52 (0.15, 1.83) | 91.8 | ||
| Caucasian (ε2/ε3) | 1,739/4,983 | 1.43 (0.79, 2.59) | 88.9 | ||
| Overall (ε2/ε4) | 3,652/10,525 | 1.81 (1.34, 2.44) | 48.3 | 0.097 | 0.827 |
| Asian (ε2/ε4) | 848/2,472 | 3.70 (1.25, 10.97) | 69.5 | ||
| Caucasian (ε2/ε4) | 2,786/7,937 | 1.44 (1.19, 1.75) | 0 | ||
| Overall (ε3/ε4) | 2,706/7,759 | 1.04 (0.86, 1.26) | 52.8 | 0.371 | 0.758 |
| Asian (ε3/ε4) | 949/2,660 | 1.22 (0.67, 2.23) | 77.3 | ||
| Caucasian (ε3/ε4) | 1,739/4,983 | 1.02 (0.88, 1.17) | 7.1 | ||
| Overall (ε2) | 5,287/24,288 | 1.23 (1.12, 1.35) | 0 | 0.229 | 0.048 |
| Asian (ε2) | 750/1,512 | 1.15 (0.85–1.56) | 0 | ||
| Caucasian (ε2) | 3,906/20,872 | 1.30 (1.17, 1.44) | 0 | ||
| African (ε2) | 255/1,002 | 1.01 (0.72, 1.42) | 0 | ||
| Overall ICH (ε2) | 5,287/24,288 | 1.23 (1.12, 1.35) | 0 | 0.229 | 0.048 |
| Hemorrhagic stroke (ε2) | 1,666/5,164 | 1.20 (1.03, 1.41) | 0 | ||
| Lobar ICH (ε2) | 1,192/4,303 | 1.36 (1.11, 1.68) | 0 | ||
| Deep ICH (ε2) | 1,255/7,776 | 1.04 (0.83, 1.31) | 0 | ||
| Overall (ε4) | 5,435/24,428 | 1.31 (1.14, 1.51) | 59.0 | 0.8 | 0.349 |
| Asian (ε4) | 903/1,572 | 1.80 (0.82, 3.91) | 86.1 | ||
| Caucasian (ε4) | 3,906/20,872 | 1.21 (1.09, 1.35) | 13.1 | ||
| African (ε4) | 255/1,002 | 1.04 (0.80, 1.34) | 0 | ||
| Overall ICH (ε4) | 2,575/16,192 | 1.31 (1.14, 1.51) | 59.0 | 0.8 | 0.349 |
| Hemorrhagic stroke (ε4) | 415/1,008 | 1.26 (0.97, 1.64) | 0 | ||
| ICH (ε4) | 1,324/4,002 | 1.27 (0.80, 2.02) | 78.8 | ||
| Lobar ICH (ε4) | 1,187/4,383 | 1.49 (1.26, 1.78) | 0 | ||
| Deep ICH (ε4) | 1,255/7,776 | 1.13 (0.94, 1.36) | 0 |
Effect size of the overall population and subgroups within the included studies of our meta-analysis.
The included studies for each analysis, along with their related details for outcome assessment, are provided in the Supplementary Table 2.
Bold values indicate statistically significant values at 95%CI (p-value < 0.05).
3.3.2 Association between the APOE ε4/ε4 genotype and the risk of hemorrhagic stroke
For the ε4/ε4 genotype, 14 studies with 2,590 cases and 7,603 controls were analyzed. A significant association was found between the ε4/ε4 genotype and increased HS risk (OR: 1.60, 95% CI = 1.21–2.13, I2 = 3.1%). Subgroup analysis showed a strong association in the Caucasian population (OR: 1.63, 95% CI = 1.20–2.20, I2 = 0%), while no significant association was observed in the Asian subgroup (OR: 1.78, 95% CI = 0.73–4.37, I2 = 34.2%). The single African study was excluded from the subgroup analysis. All findings are depicted in Figure 2b and Table 2.
3.4 Secondary outcomes
3.4.1 Association between APOE ε2/ε3 genotype and the risk of hemorrhagic stroke
In this meta-analysis, 15 studies involving 2,572 cases and 7,383 control subjects were analyzed to evaluate the ε2/ε3 genotype of the APOE gene. No significant association was found between the presence of the ε2/ε3 genotype and the risk of HS for the overall population (OR: 0.95, 95% CI = 0.54–1.65, I2 = 90.7%). During the subgroup analysis based on the ethnicities of the subjects, no significant association was observed in the Asian (OR: 0.52, 95% CI = 0.15–1.83, I2 = 91.8%) and Caucasian (OR: 1.43, 95% CI = 0.79–2.59, I2 = 88.9%) populations regarding the ε2/ε3 genotype and HS risk. The results are presented in Supplementary Figure S2-1 and Table 2.
3.4.2 Association between APOE ε2/ε4 genotype and the risk of hemorrhagic stroke
A total of 17 studies involving 3,652 cases and 10,525 control subjects were included in the meta-analysis to understand the impact of the ε2/ε4 genotype of the APOE gene on HS. We observed a significant association between the occurrence of the ε2/ε4 genotype of the APOE gene and the risk of HS in the overall population (OR: 1.81, 95% CI = 1.34–2.44, I2 = 48.3%). Additionally, during the subgroup analysis based on the ethnicities of the individual studies, both the Asian (OR: 3.70, 95% CI = 1.25–10.97, I2 = 69.5%) and Caucasian (OR: 1.44, 95% CI = 1.19–1.75, I2 = 0%) subgroups also demonstrated an association between the ε2/ε4 genotype and HS risk. The results are presented in Supplementary Figure S2-2 and Table 2.
3.4.3 Association between APOE ε3/ε4 genotype and the risk of hemorrhagic stroke
To analyze the impact of the ε3/ε4 genotype of the APOE gene on HS, we included 16 studies encompassing 2,706 cases and 7,759 control subjects. There was no significant association between HS risk and the presence of the ε3/ε4 genotype of the APOE gene in the overall population (OR: 1.04, 95% CI = 0.86–1.26, I2 = 52.8%). Subgroup analyses of ethnic populations across the different studies also demonstrated no significant association between the ε3/ε4 genotype and HS risk among the Asian (OR: 1.22, 95% CI = 0.67–2.23, I2 = 77.3%) and Caucasian (OR: 1.02, 95% CI = 0.88–1.17, I2 = 7.1%) populations. The results are illustrated in Supplementary Figure S2-3 and Table 2.
3.4.4 Association between the APOE ε2 allele and the risk of hemorrhagic stroke
To understand the impact of the ε2 allele of the APOE gene on hemorrhagic stroke (HS), we included 16 studies comprising 5,287 cases and 24,288 control subjects in this meta-analysis. We observed a significant association between the ε2 allele of the APOE gene and the risk of hemorrhagic stroke in the overall population (OR: 1.23, 95% CI = 1.12–1.35, I2 = 0%). A subgroup analysis revealed a significant association between the ε2 allele and HS risk in the Caucasian population (OR: 1.30, 95% CI = 1.17–1.44, I2 = 0%). However, no significant relationship was found in the Asian (OR: 1.15, 95% CI = 0.85–1.56, I2 = 0%) and African (OR: 1.01, 95% CI = 0.72–1.42, I2 = 0%) subgroups regarding the association between the ε2 allele and the risk of HS. The mixed and Hispanic populations could not be subgrouped because only one study was available. The results are shown in Supplementary Figure S2-4 and Table 2.
3.4.5 Association between the APOE ε4 allele and the risk of hemorrhagic stroke
This meta-analysis included 17 studies with 5,435 cases and 24,428 controls to assess the impact of the ε4 allele on hemorrhagic stroke (HS) risk. A significant association was found in the overall population (OR: 1.31, 95% CI = 1.14–1.51, I2 = 59.0%). Subgroup analysis revealed a significant association in the Caucasian population (OR: 1.21, 95% CI = 1.09–1.35, I2 = 13.1%), while no significant association was observed in Asian (OR: 1.80, 95% CI = 0.82–3.91, I2 = 86.1%) or African (OR: 1.04, 95% CI = 0.80–1.34, I2 = 0%) populations. Due to limited data, subgroup analysis for Hispanic and mixed populations was not feasible. The results are illustrated in Supplementary Figure S2-6 and Table 2.
3.5 Subgroup analysis by hemorrhage location
The APOE ε2 allele was assessed based on the location of the hemorrhagic stroke, encompassing 5,287 cases and 24,288 control subjects from 16 included studies. The locations were categorized into lobar, deep, mixed, non-lobar intracerebral hemorrhage (ICH), and rapidly involuting (RICH) or non-involuting (NICH) congenital hemangiomas. Additionally, those who could not be classified based on location were grouped under the hemorrhagic stroke category. It was found that the ε2 allele of the APOE gene had a significant association with the risk of hemorrhagic stroke for the overall location of all intracerebral hemorrhages (OR: 1.23, 95% CI = 1.12–1.35, I2 = 0%). Moreover, there was a significant association of the ε2 allele with hemorrhagic stroke risk for lobar ICH (OR: 1.36, 95% CI = 1.11–1.68, I2 = 0%). However, no significant association was observed for the deep lobar location of the hemorrhage concerning the ε2 allele and hemorrhagic stroke risk (OR: 1.04, 95% CI = 0.83–1.31, I2 = 0%). The mixed, non-lobar ICH, RICH, and NICH studies were not categorized separately because they consisted of only one study. Those with undefined locations of hemorrhagic stroke exhibited a significant association between the risk of intracerebral hemorrhage and the ε2 allele of APOE (OR: 1.20, 95% CI = 1.03–1.41, I2 = 0%). The overall results are illustrated in Supplementary Figure S2-5 and Table 2.
The association of the ε4 allele with HS risk across different hemorrhage locations was also analyzed in 17 studies with the same dataset. A significant association was found across all locations (OR: 1.31, 95% CI = 1.14–1.51, I2 = 59.0%), with a stronger link for lobar ICH (OR: 1.49, 95% CI = 1.26–1.78, I2 = 0%). However, no significant association was observed for deep ICH (OR: 1.13, 95% CI = 0.94–1.36, I2 = 0%), undefined hemorrhagic stroke (OR: 1.26, 95% CI = 0.97–1.64, I2 = 0%), or ICH with unspecified location (OR: 1.27, 95% CI = 0.80–2.02, I2 = 78.8%). Subgroup analysis for mixed, non-lobar ICH, RICH, and NICH was not possible due to limited studies. Results are depicted in Supplementary Figure S2-7 and Table 2.
3.6 Publication bias
Begg's funnel plot and Egger's test were used to assess publication bias. The symmetrical funnel plot for ε2/ε2 and ε4/ε4 genotypes suggested no bias (Figures 3a, b). Egger's test confirmed this (p = 0.494 for ε2/ε2 and 0.760 for ε4/ε4). Secondary outcomes, including ε2/ε3, ε2/ε4, ε3/ε4 genotypes and ε2, ε4 alleles, also showed no publication bias (Supplementary Figures S2-8–12). Egger's p-values for all analyses are summarized in Table 2.
Figure 3
3.7 Meta-regression analysis
Meta-regression analysis was performed to assess the effect size based on study quality. No significant deviations were observed in the association between the ε2/ε2 and ε4/ε4 genotypes of the APOE gene and HS risk (Figures 4a, b). Similarly, analyses for ε2/ε3, ε2/ε4, ε3/ε4 genotypes and ε4 allele showed no notable deviations. However, the ε2 allele exhibited some deviation (p = 0.048), suggesting cautious interpretation of its association with HS risk. Table 2 summarizes the meta-regression p-values, with additional details in Supplementary Figures S2-13–17.
Figure 4
3.8 Sensitivity analysis
Sensitivity analysis using the Leave-one-out method showed no significant changes in effect size for the ε2/ε2 and ε4/ε4 genotypes of the APOE gene and HS risk (Figures 5a, b). Similarly, no notable variations were observed for ε2/ε3, ε2/ε4, ε3/ε4 genotypes or ε2 and ε4 alleles (Supplementary Figures S2-18–22), confirming the robustness of the findings.
Figure 5
4 Discussion
This systematic review and meta-analysis included 24 studies with 8,269 HS cases and 26,321 controls across various ethnicities, primarily Caucasian and Asian. Significant associations were observed between ε2/ε2, ε4/ε4, and ε2/ε4 genotypes and HS risk. Both ε2 and ε4 alleles were linked to increased HS risk, with no significant associations for other APOE variants.
4.1 Ethnicity-based and hemorrhage location subgroup analyses
Subgroup analysis confirmed significant associations between ε2/ε2, ε4/ε4, and ε2/ε4 genotypes and HS risk in Caucasian populations. In Asian populations, only the ε2/ε4 genotype showed a significant risk association. Further analysis by hemorrhage location revealed that ε2 and ε4 alleles were strongly linked to lobar hemorrhages, whereas no association was found with deep hemorrhages.
4.2 Comparison with previous meta-analyses
Our findings align with (Nie et al. 2019), which identified ε2 and ε4 alleles as risk factors for intracerebral hemorrhage (ICH) in Caucasians, but with a significantly larger sample (24 vs. eight studies). Similarly, our results corroborate (Marini et al. 2019), who found a strong link between ε2 and ε4 alleles and lobar ICH in Caucasians, with our larger dataset reinforcing their conclusions. Additionally, (Pan et al. 2021) demonstrated poor functional outcomes in ICH patients with the ε4 allele, further supporting our findings.
4.3 APOE and its broader clinical implications
Beyond HS, the APOE gene has been extensively studied in neurodegenerative diseases, including Alzheimer's disease, where the ε4 allele is a well-established risk factor across ethnicities, including Indian populations (Farrer et al., 1997; Agarwal and Tripathi, 2014). APOE polymorphisms are also linked to lipid metabolism, cardiovascular diseases, and stroke risk, with associations found between APOE alleles and cholesterol levels, atherosclerosis, and oxidative injury protection (Ozen et al., 2022).
4.4 Unresolved mechanisms and future directions
Conflicting evidence exists regarding the mechanisms behind APOE polymorphisms and HS risk. While ε2 and ε4 alleles are implicated in abnormal lipid metabolism, blood-brain barrier disruption, and vasogenic edema, some studies suggest APOE presence may protect against oxidative neuronal damage. Our study, the most extensive meta-analysis to date on APOE polymorphisms and HS, strengthens the link between ε2 and ε4 alleles and HS risk (Biffi et al., 2010; Zhang et al., 2014; Sudlow et al., 2006). These findings provide a robust foundation for future observational studies on APOE genotypes and their role in HS, offering potential clinical implications for risk stratification and targeted interventions. These findings can provide a guideline for conducting future observational studies on APOE genotypes to ascertain the relationship with the risk of HS, thereby facilitating clinical transition.
4.5 Limitations
Despite its comprehensive approach, this study has some limitations. Key comorbidities like hypertension, diabetes, and prior stroke or cardiac disease were not accounted for, potentially influencing outcomes. False discovery rates were not assessed, which may affect comparisons. Some heterogeneity was noted, with meta-regression indicating bias; however, this was addressed through the random-effects model and sensitivity analyses. Importantly, the study demonstrated minimal heterogeneity and no publication bias, reinforcing the reliability of the pooled effect sizes. The lack of risk factor, confounder, and covariate data in the included studies limits the generalizability of the study outcomes and, hence, the results must be interpreted with caution.
5 Conclusions
This meta-analysis provides a comprehensive evaluation of the association between APOE alleles and hemorrhagic stroke (HS) risk. Significant associations were identified for ε2/ε2, ε4/ε4, and ε2/ε4 genotypes, as well as ε2 and ε4 alleles, with HS risk in both the overall and Caucasian populations. Additionally, a significant link between the ε2/ε4 genotype and HS risk was observed in the Asian population. These findings highlight the need for large-scale prospective studies to further validate these associations.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
MN: Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. AR: Data curation, Formal analysis, Investigation, Writing – original draft. SM: Conceptualization, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing. PK: Conceptualization, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fstro.2026.1684121/full#supplementary-material
References
1
AgarwalR.TripathiC. B. (2014). Association of apolipoprotein E genetic variation in Alzheimer's disease in Indian population: a meta-analysis. Am. J. Alzheimers Dis. Other Demen.29, 575–582. doi: 10.1177/1533317514531443
2
AtadzhanovM.MwabaM. H.MukomenaP. N.LakhiS.RayaproluS.RossO. A.et al. (2013). Association of the APOE, MTHFR and ACE genes polymorphisms and stroke in Zambian patients. Neurol. Int.5:e20. doi: 10.4081/ni.2013.e20
3
BasunH.CorderE. H.GuoZ.LannfeltL.CorderL. S.MantonK. G.et al. (1996). Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke27, 1310–1315. doi: 10.1161/01.STR.27.8.1310
4
BeggC. B.MazumdarM. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics50, 1088–1101. doi: 10.2307/2533446
5
BiffiA.SonniA.AndersonC. D.KisselaB.JagiellaJ. M.SchmidtH.et al. (2010). Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann. Neurol.68, 934–943. doi: 10.1002/ana.22134
6
CattoA.CarterA. M.BarrettJ. H.SticklandM.BamfordJ.DaviesJ. A.et al. (1996). Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Stroke27, 435–440. doi: 10.1161/01.STR.27.3.435
7
ChowdhuryA. H.YokoyamaT.KokuboY.ZamanM. M.HaqueA.TanakaH.et al. (2001). Apolipoprotein E genetic polymorphism and stroke subtypes in a Bangladeshi hospital-based study. J. Epidemiol.11, 131–138. doi: 10.2188/jea.11.131
8
DasS.KaulS.JyothyA.MunshiA. (2016). Association of APOE (E2, E3 and E4) gene variants and lipid levels in ischemic stroke, its subtypes and hemorrhagic stroke in a South Indian population. Neurosci. Lett.628, 136–141. doi: 10.1016/j.neulet.2016.06.032
9
de RooijN. K.LinnF. H. H.van der PlasJ. A.AlgraA.RinkelG. J. E. (2007). Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J. Neurol. Neurosurg. Psychiatr.78, 1365–1372. doi: 10.1136/jnnp.2007.117655
10
DerSimonianR. (1996). Meta-analysis in the design and monitoring of clinical trials. Stat. Med. 15, 1237–1248. discussion 1249–1252. doi: 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N
11
DuzenliS.PirimI.GepdiremenA.DenizO. (2004). Apolipoprotein E polymorphism and stroke in a population from Eastern Turkey. J. Neurogenet. 18, 365–375. doi: 10.1080/01677060490500294
12
EggerM.SmithG. D.SchneiderM.MinderC. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ315, 629–634. doi: 10.1136/bmj.315.7109.629
13
FarrerL. A.CupplesL. A.HainesJ. L.HymanB.KukullW. A.MayeuxR.et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356. doi: 10.1001/jama.1997.03550160069041
14
FeiginV. L.StarkB. A.JohnsonC. O.RothG. A.BisignanoC.AbadyG. G.et al. (2021). Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol.20, 795–820. doi: 10.1016/S1474-4422(21)00252-0
15
GanaieH. A.BiswasA.BhattacharyaA. P.PalS.RayJ.DasS. K.et al. (2020). Association of APOE gene polymorphism with stroke patients from Rural Eastern India. Ann. Indian Acad. Neurol.23, 504–509. doi: 10.4103/aian.AIAN_45_19
16
GarciaC.Pinho e MeloT.RochaL.LechnerM. C. (1999). Cerebral hemorrhage and apoE. J. Neurol.246, 830–834. doi: 10.1007/s004150050463
17
GreenbergS. M.BriggsM. E.HymanB. T.KokorisG. J.TakisC.KanterD. S.et al. (1996). Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke27, 1333–1337. doi: 10.1161/01.STR.27.8.1333
18
HigginsJ. P. T.ThompsonS. G.DeeksJ. J.AltmanD. G. (2003). Measuring inconsistency in meta-analyses. BMJ327, 557–560. doi: 10.1136/bmj.327.7414.557
19
HostettlerI. C.SeiffgeD.WongA.AmblerG.WilsonD.ShakeshaftC.et al. (2022). APOE and cerebral small vessel disease markers in patients with intracerebral hemorrhage. Neurology99, e1290–e1298. doi: 10.1212/WNL.0000000000200851
20
HuangY.MahleyR. W. (2014). Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol. Dis. 72(Pt A), 3–12. doi: 10.1016/j.nbd.2014.08.025
21
JiangL.SunX.XieY.DanW.XiaY.XuR.et al. (2024). Effect of APOE gene on cerebral oxygen saturation, cerebral electrical activity and prognosis after intracerebral hemorrhage. Int. J. Biol. Macromol.279:135392. doi: 10.1016/j.ijbiomac.2024.135392
22
KansagaraD.O'NeilM.NugentS.FreemanM.LowA.KondoK.et al. (2017). [Table], Quality Assessment Criteria for Observational Studies, Based on the Newcastle-Ottawa Scale. Available online at: https://www.ncbi.nlm.nih.gov/books/NBK476448/table/appc.t4/ (Accessed April 3, 2021).
23
KokuboY.ChowdhuryA. H.DateC.YokoyamaT.SobueH.TanakaH.et al. (2000). Age-dependent association of apolipoprotein E genotypes with stroke subtypes in a Japanese rural population. Stroke31, 1299–1306. doi: 10.1161/01.STR.31.6.1299
24
MantelN.HaenszelW. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst.22, 719–748.
25
MariniS.CrawfordK.MorottiA.LeeM. J.PezziniA.MoomawC. J.et al. (2019). Association of apolipoprotein E with intracerebral hemorrhage risk by race/ethnicity: a meta-analysis. JAMA Neurol.76, 480–491. doi: 10.1001/jamaneurol.2018.4519
26
MartiniS. R.FlahertyM. L.BrownW. M.HaverbuschM.ComeauM. E.SauerbeckL. R.et al. (2012). Risk factors for intracerebral hemorrhage differ according to hemorrhage location. Neurology79, 2275–2282. doi: 10.1212/WNL.0b013e318276896f
27
McCarronM. O.NicollJ. A. (1998). High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neurosci. Lett.247, 45–48. doi: 10.1016/S0304-3940(98)00286-9
28
MisraU. K.KalitaJ.SomarajanB. I. (2013). Recurrent intracerebral hemorrhage in patients with hypertension is associated with APOE gene polymorphism: a preliminary study. J. Stroke Cerebrovasc. Dis.22, 758–763. doi: 10.1016/j.jstrokecerebrovasdis.2012.02.006
29
NakataY.KatsuyaT.RakugiH.TakamiS.SatoN.KamideK.et al. (1997). Polymorphism of angiotensin converting enzyme, angiotensinogen, and apolipoprotein E genes in a Japanese population with cerebrovascular disease. Am. J. Hypertens. 10 (12 Pt 1), 1391–1395. doi: 10.1016/S0895-7061(97)00315-4
30
NieH.HuY.LiuN.ZhangP.LiG.LiY.et al. (2019). Apolipoprotein E gene polymorphisms are risk factors for spontaneous intracerebral hemorrhage: a systematic review and meta-analysis. Curr. Med. Sci. 39, 111–117. doi: 10.1007/s11596-019-2007-5
31
OzenE.MihaylovaR. G.LordN. J.LovegroveJ. A.JacksonK. G. (2022). Association between APOE genotype with body composition and cardiovascular disease risk markers is modulated by BMI in healthy adults: findings from the BODYCON study. Int. J. Mol. Sci.23:9766. doi: 10.3390/ijms23179766
32
PageM. J.McKenzieJ. E.BossuytP. M.BoutronI.HoffmannT. C.MulrowC. D.et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ372:n71. doi: 10.1136/bmj.n71
33
PanW.ZhangM.GuoZ.XiaoW.YouC.XueL.et al. (2021). Association between apolipoprotein E polymorphism and clinical outcome after ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Cerebrovasc. Dis.51, 313–322. doi: 10.1159/000520053
34
SawyerR. P.SekarP.OsborneJ.KittnerS. J.MoomawC. J.FlahertyM. L.et al. (2018). Racial/ethnic variation of APOE alleles for lobar intracerebral hemorrhage. Neurology91, e410–e420. doi: 10.1212/WNL.0000000000005908
35
ScienceDirect Topics (n.d.). Apolipoprotein E3—An Overview. Available online at: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/apolipoprotein-e3 (Accessed December 23 2022).
36
SeifertT.LechnerA.FloohE.SchmidtH.SchmidtR.FazekasF.et al. (2006). Lack of Association of lobar intracerebral hemorrhage with apolipoprotein E genotype in an unselected population. Cerebrovasc. Dis.21, 266–270. doi: 10.1159/000091225
37
SudlowC.Martínez GonzálezN. A.KimJ.ClarkC. (2006). Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke37, 364–370. doi: 10.1161/01.STR.0000199065.12908.62
38
TasdemirN.TamamY.ToprakR.TamamB.TasdemirM. S. (2008). Association of apolipoprotein E genotype and cerebrovascular disease risk factors in a Turkish population. Int. J. Neurosci.118, 1109–1129. doi: 10.1080/00207450701769190
39
UnnithanA. K. A.DasM. J.MehtaP. (2022). Hemorrhagic Stroke—StatPearls. Treasure Island, FL: StatPearls Publishing.
40
WangS.ZouX.-L.WuL.-X.ZhouH.-F.XiaoL.YaoT.et al. (2022). Epidemiology of intracerebral hemorrhage: a systematic review and meta-analysis. Front. Neurol.13:915813. doi: 10.3389/fneur.2022.915813
41
WHO (n.d.). EMRO | Stroke, Cerebrovascular Accident | Health Topics. Geneva: World Health Organization—Regional Office for the Eastern Mediterranean. Available online at: http://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html (Accessed December 21, 2022).
42
WooD.DekaR.FalconeG. J.FlahertyM. L.HaverbuschM.MartiniS. R.et al. (2013). Apolipoprotein E, statins, and risk of intracerebral hemorrhage. Stroke44, 3013–3017. doi: 10.1161/STROKEAHA.113.001304
43
WooD.KaushalR.ChakrabortyR.WooJ.HaverbuschM.SekarP.et al. (2005). Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke36, 1874–1879. doi: 10.1161/01.STR.0000177891.15082.b9
44
WooD.SauerbeckL. R.KisselaB. M.KhouryJ. C.SzaflarskiJ. P.GebelJ.et al. (2002). Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke33, 1190–1195. doi: 10.1161/01.STR.0000014774.88027.22
45
ZhangR.WangX.LiuJ.YangS.TangZ.LiS.et al. (2012). Apolipoprotein E gene polymorphism and the risk of intracerebral hemorrhage in the Chinese population. Genet. Test Mol. Biomark. 16, 63–66. doi: 10.1089/gtmb.2011.0103
46
ZhangR.WangX.TangZ.LiuJ.YangS.ZhangY.et al. (2014). Apolipoprotein E gene polymorphism and the risk of intracerebral hemorrhage: a meta-analysis of epidemiologic studies. Lipids Health Dis.13:47. doi: 10.1186/1476-511X-13-47
Summary
Keywords
APOE alleles, APOE genotype, Apolipoprotein E, hemorrhagic stroke, intracerebral hemorrhage
Citation
Nath M, Rai A, Misra S and Kumar P (2026) The APOE paradox: divergent genetic influences on hemorrhagic stroke risk—A meta-analysis. Front. Stroke 5:1684121. doi: 10.3389/fstro.2026.1684121
Received
12 August 2025
Revised
20 January 2026
Accepted
30 January 2026
Published
04 March 2026
Volume
5 - 2026
Edited by
Yousef Hannawi, The Ohio State University, United States
Reviewed by
Myriam Fornage, University of Texas Health Science Center at Houston, United States
Jan Bressler, University of Texas Health Science Center at Houston, United States
Updates
Copyright
© 2026 Nath, Rai, Misra and Kumar.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pradeep Kumar, pradeepguptaneuro@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.